[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553043":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":35,"responsibleParty":105,"collaborators":107,"id":111,"slug":112,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":113,"sex":118,"minAge":119,"maxAge":10,"enrollmentInfo":120,"targetDuration":123,"studyType":124,"phases":10,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"Cardiovascular and Interventional Radiological Society of Europe","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Full cohort",null,"Cryoablation with curative-intent of bone metastases from oligometastatic or bone oligo-progressive disease.",[13],"Device: Cryoablation system",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Cryoablation system","Any cryoablation system from Boston Scientific that has received CE Mark and\u002For FDA clearance for the ablation of bone malignancies.",[9],[21],{"name":22,"affiliation":23,"role":24},"Roberto L Cazzato, Dr","Strasbourg University Hospitals, Strasbourg, France","STUDY_CHAIR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Claire E Poulet, PhD","CONTACT","+41 79 385 16 78","borealis@cirse.org",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Dhwani S. Korde, PhD","+4367762942469","borealise@cirse.org",[36,53,65,77,91],{"facility":37,"status":38,"city":39,"state":10,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Institute Bergonié","RECRUITING","Bordeaux","33076","France","FR",{"type":44,"coordinates":45},"Point",[46,47],-0.58046,44.84124,{"lat":47,"lon":46},[50],{"name":51,"role":52,"phone":10,"phoneExt":10,"email":10},"Xavier Buy, Dr","PRINCIPAL_INVESTIGATOR",{"facility":54,"status":38,"city":55,"state":10,"zip":56,"country":41,"countryCode":42,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"CHRU de Strasbourg","Strasbourg","67200",{"type":44,"coordinates":58},[59,60],7.74553,48.58392,{"lat":60,"lon":59},[63],{"name":64,"role":52,"phone":10,"phoneExt":10,"email":10},"Roberto Luigi Cazzato, Dr",{"facility":66,"status":38,"city":67,"state":10,"zip":68,"country":41,"countryCode":42,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Institut Gustave Roussy","Villejuif","94805",{"type":44,"coordinates":70},[71,72],2.35992,48.7939,{"lat":72,"lon":71},[75],{"name":76,"role":52,"phone":10,"phoneExt":10,"email":10},"Frederic Deschamps, Dr",{"facility":78,"status":38,"city":79,"state":10,"zip":80,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Hospital Universitario y Politécnico La Fe","Valencia","46026","Spain","ES",{"type":44,"coordinates":84},[85,86],-0.37966,39.47391,{"lat":86,"lon":85},[89],{"name":90,"role":52,"phone":10,"phoneExt":10,"email":10},"Fernando Gómez Muñoz, Dr",{"facility":92,"status":38,"city":93,"state":10,"zip":94,"country":95,"countryCode":96,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"CHUV-Lausanne University Hospital","Lausanne","1011","Switzerland","CH",{"type":44,"coordinates":98},[99,100],6.63282,46.516,{"lat":100,"lon":99},[103],{"name":104,"role":52,"phone":10,"phoneExt":10,"email":10},"Georgia Tsoumakidou, Dr",{"type":106,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[108],{"name":109,"class":110},"Boston Scientific Corporation","INDUSTRY","100553043","bone-metastases-registry-for-patients-undergoing-cryoablation-with-curative-purpose-100553043",false,"NCT06480955","BOne Metastases REgistry for Patients Undergoing cryoAbLation With curatIve purpoSe","BOREALIS","Inclusion Criteria:\n\n* Bone metastases in patients with oligometastatic disease (\\\u003C5 bone\u002Fvisceral metastases) or bone oligo-progressive disease (visceral or osseous multi-metastatic disease stable under systemic treatment except 1-3 progressing bone metastases) from solid tumours;\n* Number of target lesions ≤ 3\n* Size of target lesion(s) \\\u003C 5 cm (largest diameter);\n* Referral to local ablative treatment by multidisciplinary tumour board (MDTB);\n* Treatment by percutaneous cryoablation with curative intent (i.e., complete tumour destruction) assessed as technically feasible by the IR in charge;\n* Procedure performed with a cryoablation system from Boston Scientific.\n\nExclusion Criteria:\n\n* \\\u003C 18 years old;\n* Incapacity or refusal to give informed consent;\n* Ongoing pregnancy;\n* Health status not compatible with the minimum meaningful follow-up period (i.e., 12 months):\n\n  * Karnofsky Performance Scale \\\u003C 60%, or\n  * Bone metastases originating from rapidly evolving tumour histologies not allowing reasonable life expectancy of at least 12 months, or\n  * Life expectancy \\\u003C 12 months\n* Infection of treatment site or systemic infection;\n* Uncorrectable coagulopathy;\n* Haematological disease (including multiple myeloma and plasmacytoma);\n* Concomitant radiation therapy or radiation therapy within 12 weeks before the planned cryoablation procedure.","ALL","18 Years",{"count":121,"type":122},50,"ESTIMATED","1 Year","OBSERVATIONAL","BOREALIS is a multicentre, prospective, observational cohort study designed to investigate the effectiveness, feasibility, safety and impact on pain and quality of life of curative-intent cryoablation for the treatment of bone metastases in patients with oligometastatic or bone oligo-progressive disease.",[127],"Bone Metastases",[129,130,131,132],"Cryoablation Oligo-progressive disease","Bone metastases","Oligometastatic Disease","Oligo-progressive disease","2025-12-23",{"date":135,"type":136},"2025-12-30","ACTUAL",{"date":138,"type":136},"2025-04-01",{"date":140,"type":122},"2028-04",{"name":5,"class":6},5]